These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

103 related articles for article (PubMed ID: 27685159)

  • 21. High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers.
    Jacot W; Mollevi C; Fina F; Lopez-Crapez E; Martin PM; Colombo PE; Bibeau F; Romieu G; Lamy PJ
    BMC Cancer; 2015 Dec; 15():986. PubMed ID: 26680641
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Outcome of triple negative breast cancer: comparison of sporadic and BRCA1-associated cancers.
    Tung N; Gaughan E; Hacker MR; Lee LJ; Alexander B; Poles E; Schnitt SJ; Garber JE
    Breast Cancer Res Treat; 2014 Jul; 146(1):175-82. PubMed ID: 24839033
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of PD-L1 Expression and Associated Tumor-Infiltrating Lymphocytes in Laryngeal Squamous Cell Carcinoma.
    Vassilakopoulou M; Avgeris M; Velcheti V; Kotoula V; Rampias T; Chatzopoulos K; Perisanidis C; Kontos CK; Giotakis AI; Scorilas A; Rimm D; Sasaki C; Fountzilas G; Psyrri A
    Clin Cancer Res; 2016 Feb; 22(3):704-13. PubMed ID: 26408403
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
    Cossu-Rocca P; Orrù S; Muroni MR; Sanges F; Sotgiu G; Ena S; Pira G; Murgia L; Manca A; Uras MG; Sarobba MG; Urru S; De Miglio MR
    PLoS One; 2015; 10(11):e0141763. PubMed ID: 26540293
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Automated mitotic spindle hotspot counts are highly associated with clinical outcomes in systemically untreated early-stage triple-negative breast cancer.
    Leon-Ferre RA; Carter JM; Zahrieh D; Sinnwell JP; Salgado R; Suman VJ; Hillman DW; Boughey JC; Kalari KR; Couch FJ; Ingle JN; Balkenhol M; Ciompi F; van der Laak J; Goetz MP
    NPJ Breast Cancer; 2024 Mar; 10(1):25. PubMed ID: 38553444
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Predictive Biomarker Profiling of > 6000 Breast Cancer Patients Shows Heterogeneity in TNBC, With Treatment Implications.
    Millis SZ; Gatalica Z; Winkler J; Vranic S; Kimbrough J; Reddy S; O'Shaughnessy JA
    Clin Breast Cancer; 2015 Dec; 15(6):473-481.e3. PubMed ID: 26051240
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tumor-infiltrating lymphocytes are correlated with response to neoadjuvant chemotherapy in triple-negative breast cancer.
    Ono M; Tsuda H; Shimizu C; Yamamoto S; Shibata T; Yamamoto H; Hirata T; Yonemori K; Ando M; Tamura K; Katsumata N; Kinoshita T; Takiguchi Y; Tanzawa H; Fujiwara Y
    Breast Cancer Res Treat; 2012 Apr; 132(3):793-805. PubMed ID: 21562709
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment.
    Chang HR; Glaspy J; Allison MA; Kass FC; Elashoff R; Chung DU; Gornbein J
    Cancer; 2010 Sep; 116(18):4227-37. PubMed ID: 20549829
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumour infiltrating lymphocytes (TILs) in breast cancer during pregnancy.
    Azim HA; Vingiani A; Peccatori F; Viale G; Loi S; Pruneri G
    Breast; 2015 Jun; 24(3):290-3. PubMed ID: 25702955
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinicopathological and prognostic significance of FOXP3+ tumor infiltrating lymphocytes in patients with breast cancer: a meta-analysis.
    Jiang D; Gao Z; Cai Z; Wang M; He J
    BMC Cancer; 2015 Oct; 15():727. PubMed ID: 26475790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Significance of PIK3CA Mutations in Patients with Early Breast Cancer Treated with Adjuvant Chemotherapy: A Hellenic Cooperative Oncology Group (HeCOG) Study.
    Papaxoinis G; Kotoula V; Alexopoulou Z; Kalogeras KT; Zagouri F; Timotheadou E; Gogas H; Pentheroudakis G; Christodoulou C; Koutras A; Bafaloukos D; Aravantinos G; Papakostas P; Charalambous E; Papadopoulou K; Varthalitis I; Efstratiou I; Zaramboukas T; Patsea H; Scopa CD; Skondra M; Kosmidis P; Pectasides D; Fountzilas G
    PLoS One; 2015; 10(10):e0140293. PubMed ID: 26452060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Triple-negative breast cancer: the impact of guideline-adherent adjuvant treatment on survival--a retrospective multi-centre cohort study.
    Schwentner L; Wolters R; Koretz K; Wischnewsky MB; Kreienberg R; Rottscholl R; Wöckel A
    Breast Cancer Res Treat; 2012 Apr; 132(3):1073-80. PubMed ID: 22205141
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD3+, CD4+ & CD8+ tumour infiltrating lymphocytes (TILs) are predictors of favourable survival outcome in infiltrating ductal carcinoma of breast.
    Rathore AS; Kumar S; Konwar R; Makker A; Negi MP; Goel MM
    Indian J Med Res; 2014 Sep; 140(3):361-9. PubMed ID: 25366203
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases.
    Harter PN; Bernatz S; Scholz A; Zeiner PS; Zinke J; Kiyose M; Blasel S; Beschorner R; Senft C; Bender B; Ronellenfitsch MW; Wikman H; Glatzel M; Meinhardt M; Juratli TA; Steinbach JP; Plate KH; Wischhusen J; Weide B; Mittelbronn M
    Oncotarget; 2015 Dec; 6(38):40836-49. PubMed ID: 26517811
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The repertoire of somatic genetic alterations of acinic cell carcinomas of the breast: an exploratory, hypothesis-generating study.
    Guerini-Rocco E; Hodi Z; Piscuoglio S; Ng CK; Rakha EA; Schultheis AM; Marchiò C; da Cruz Paula A; De Filippo MR; Martelotto LG; De Mattos-Arruda L; Edelweiss M; Jungbluth AA; Fusco N; Norton L; Weigelt B; Ellis IO; Reis-Filho JS
    J Pathol; 2015 Oct; 237(2):166-78. PubMed ID: 26011570
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of BRCA germline mutations on breast cancer prognosis: A systematic review and meta-analysis.
    Baretta Z; Mocellin S; Goldin E; Olopade OI; Huo D
    Medicine (Baltimore); 2016 Oct; 95(40):e4975. PubMed ID: 27749552
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC).
    Tomioka N; Azuma M; Ikarashi M; Yamamoto M; Sato M; Watanabe KI; Yamashiro K; Takahashi M
    Breast Cancer; 2018 Jan; 25(1):34-42. PubMed ID: 28488168
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Programmed Death Ligand 1 (PD-L1) Tumor Expression Is Associated with a Better Prognosis and Diabetic Disease in Triple Negative Breast Cancer Patients.
    Botti G; Collina F; Scognamiglio G; Rao F; Peluso V; De Cecio R; Piezzo M; Landi G; De Laurentiis M; Cantile M; Di Bonito M
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28230773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance of tumor-infiltrating lymphocytes in breast cancer.
    Stanton SE; Disis ML
    J Immunother Cancer; 2016; 4():59. PubMed ID: 27777769
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pathogenic mutations and overall survival in 3,084 patients with cancer: the Hellenic Cooperative Oncology Group Precision Medicine Initiative.
    Fountzilas E; Kotoula V; Koliou GA; Giannoulatou E; Gogas H; Papadimitriou C; Tikas I; Zhang J; Papadopoulou K; Zagouri F; Christodoulou C; Koutras A; Makatsoris T; Chrisafi S; Linardou H; Varthalitis I; Papatsibas G; Razis E; Papakostas P; Samantas E; Aravantinos G; Bafaloukos D; Kosmidis P; Koumarianou A; Psyrri A; Pentheroudakis G; Pectasides D; Futreal A; Fountzilas G; Tsimberidou AM
    Oncotarget; 2020 Jan; 11(1):1-14. PubMed ID: 32002119
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.